



## **Attenuation of Fructose Induced Hyperlipidemia of *Enicostemma axillare***

U.Subasini<sup>1</sup>, S. Thenmozhi<sup>1</sup>, D. Sathyamurthy<sup>1</sup>, G.Victor Rajamanickam<sup>2</sup>

<sup>1</sup>Swamy Vivekanandha College of Pharmacy, Namakkal, Thiruchengode – 637 205, India.

<sup>2</sup>Sri Sairam Group of Institutions, Medical Campus, West Tambaram, Chennai – 44, India.

**Received on:** 28/02/2012

**Accepted on:** 30/04/2012

### **ABSTRACT**

*Hypercholesterolemia has become the leading cause for the development of various diseases. It has drawn the attention of pharmaceutical companies to turn towards the herbal products, having fewer side effects. Preliminary phytochemical analyses were carried out in different extracts of *Enicostemma axillare* (EA) like hexane, chloroform, ethyl acetate and 85 % methanol. The hypocholesterolaemic effect of 85 % methanolic extract of EA were evaluated in fructose induced hyperlipidemic animals. Antioxidant enzymes such as catalase, TBARS, GSH, GST and lipid profile such as cholesterol, LDL, VLDL, HDL and triglycerides were analysed in heart and plasma samples. Administration of EA decreases the lipid profile and TBARS significantly ( $p < 0.05$ ). Likewise, EA administration increases the antioxidant activity and HDL significantly ( $p < 0.05$ ). The results reveal that EA is a rich source for phytoconstituents like tannin, Vitamin C and Vitamin E and can be used as a potent hypocholesterolemic and antioxidant agent in pharmaceutical industry. In the present research, the hypocholesterolaemic activity of EA along with their phytochemical evaluation has been done.*

**Key Words:** Antioxidants, Hypocholesterolaemia, *Enicostemma axillare*, Fructose, Lipid profile.

### **INTRODUCTION**

Heart disease is the leading cause of death. Many of the risk factors like smoking, lack of exercise and consumption of a high fat diet are responsible for causing heart disease. However, a healthy diet is felt important for both prevention and treatment of cardiovascular disease.<sup>1</sup> Hypercholesterolaemia is a well-recognized risk factor for coronary artery disease.<sup>2</sup> "Atherosclerosis" is the primary factor leading to coronary heart disease. It is the commonest cause of death in industrialized world in addition to stroke and peripheral vascular disease, which are treated as a major cause of morbidity and mortality.<sup>3</sup>

Increased intake of food may be related to oxidative stress<sup>4,5</sup> has observed that increased caloric intake is an important factor in decreasing the mitochondrial membrane fluidity and increasing the reactive oxygen species generation. Antioxidant substances are believed to suppress the onset and development of atherosclerosis. Compounds such as probucol have shown effect to

reduce the progression of atherosclerosis lesions in hyperlipidaemic rabbits.<sup>6</sup> In addition, flavonoids and phenolic compounds have also seen to have antioxidant effect.<sup>7</sup> Plant polyphenol exert cardiovascular benefits by altering concentrations of blood lipid components and a high intake of polyphenols can significantly reduce the risk of mortality from cardiovascular disease.<sup>8</sup> Plants are the source of medicinal agents since time immemorial from the dawn of civilization. People are utilizing the important biological properties of various plants for the treatment of different diseases. Even today, plants are the most exclusive source of drugs for the majority of the world population and plant products constitute about 25 % of prescribed medicine.<sup>9</sup>

*Enicostemma axillare* (EA) is used as a laxative, anti-inflammatory and also as liver tonic. The anti-tumor activity of methanolic extract of EA has been evaluated against Dolton's ascetic lymphoma in swiss albino mice.<sup>10</sup> *E.axillare* is slightly effective against malaria.<sup>11</sup> The aqueous extract of

the plant reduce the blood sugar of diabetic animals.<sup>12</sup>

In the present study, we have attempted to quantify the phytoconstituents in different extracts of EA along with the evaluation of hypocholesterolaemic and antioxidant activity of phyto-constituents rich extract.

## MATERIALS AND METHODS

### Plant Materials

The root of EA was collected from Madurai district, Tamil Nadu, India, dried under shade and coarsely powdered. The plant material was identified by the Centre for Advanced Research in Indian System of Medicine (CARISM), SASTRA University, Thanjavur, Tamil Nadu, India.

### Extraction

The plant material was soaked in different solvents like hexane, chloroform, ethyl acetate and 85 % methanol. The extract was concentrated *In-vacuo*. The concentrated extract was stored in a desiccator until used for experiments. The yield of extract was calculated as 1.86 % in hexane, 2.52 % in chloroform, 1.56 % in ethyl acetate and 3.34 % in 85 % methanol extract.

### Preliminary Phytochemical Analysis

The concentration of total phenolic content<sup>13</sup> tannin,<sup>14</sup> carbohydrate,<sup>15</sup> Vitamin C<sup>16</sup> and Vitamin E<sup>17</sup> were estimated in raw plant of EA. The EA extract was tested for the presence of various phytoconstituents like flavonoids, tannin and alkaloids by following the method of Trease and Evans (1996).<sup>18</sup>

### Evaluation of EA on Hypocholesterolaemic Activity

#### Experimental animals

Albino Wistar Rats of 150-200 g were obtained from Central GLP complainant animal house, Centre for Advanced Research in Indian System of Medicine, SASTRA University, Tamil Nadu, India. They were housed under standard environmental conditions of temperature (22±2°C) and relative humidity of 30-70 %. A 12:12 h light/dark cycle was followed. All animals had free access to water and standard pellets of laboratory animals diet. This study was reviewed and approved by the Institutional animal ethical committee (Reg.No. 817/04/ac/cpsea).

#### Experimental protocol for Fructose induced hyperlipidemia

Rats were divided into 4 groups as follows. Each group consisted of six animals. 10 % fructose was

used as inducing agent for hyperlipidaemia. The animals were treated with fructose along with extract for 21 days.

Group 1 - Water

Group 2 - 10 % Fructose in distilled water/kg b.wt.

Group 3 - 10 % Fructose in distilled water/kg b.wt., +150 mg/kg b.wt., of extract

Group 4 - 10 % Fructose in distilled water/kg b.wt., +250 mg/kg b.wt., of extract

On 21<sup>st</sup> day, all the animals were allowed for overnight fasting. The animals were sacrificed by decapitation in anesthetized condition. Volatile anesthetic agent was used for anesthesia. The heart was excised, washed in saline and homogenized in Tris buffer (0.1 M, pH 7.4). Lipid was extracted from the portion of the heart by following the method of Folch *et al.*, (1957)<sup>19</sup>. Plasma was separated by centrifuging at 2000 rpm for 10 minutes. Various antioxidants like Lipid peroxidation (TBARS)<sup>20</sup> Glutathione peroxidase (GPx)<sup>21</sup> Reduced glutathione (GSH)<sup>22</sup> and catalase<sup>23</sup> were analyzed. Plasma total cholesterol and High Density Lipoprotein – Cholesterol (HDL-C) concentrations were determined using enzymatic kits from Randox Laboratories Ltd., United Kingdom.<sup>24</sup> HDL-C was analyzed after precipitation of apo B-containing lipoproteins with dextran sulfate.<sup>25</sup> In heart homogenate, total cholesterol and HDL concentration were estimated by following the method of Zak.<sup>26</sup> Triglycerides concentration of Plasma and heart homogenate (TGL) concentrations were determined by Foster and Dunn (1973).<sup>27</sup> Very Low Density Lipoprotein (VLDL) is TGL/5. Low Density Lipoprotein - Cholesterol (LDL-C) concentrations were then determined using the Friedewald equation.<sup>28</sup>

### Statistical analysis

Values are of Mean ± Standard Error (SE) (n=6). Significant difference has been observed using one Way Analysis of Variance (ANOVA) using Duncan Multiple Range test (DMRT). Values not sharing common alphabets (a, b, ab, c,d) are found to differ significantly at p<0.05.

## RESULTS

The EA was observed to be a rich source of phytoconstituents like phenol, tannin, carbohydrate and, vitamins like Vitamin C and Vitamin E. The percentage yield of all the phytoconstituents in 85 % methanolic extract was found to be lower than that of completely raw plant (Table-1).

Qualitative analysis of EA extract showed the presence of various phytoconstituents. alkaloids and phytosterol were eluted in hexane and chloroform extracts. Flavonoids, polyphenols and phytosterol were eluted in ethyl acetate extract.

85 % methanolic extract has proved positive for flavonoids, polyphenols, phytosterol and carbohydrate (Table-2).

Fructose administration was observed to increase the level of lipid profile like total cholesterol, LDL, VLDL and TGL in both plasma and heart homogenate ( $p < 0.05$ , Table III). On treating animals with EA extract at the dose of 150 and 250 mg/kg b.wt., all the above mentioned lipid profiles were found to be decreased significantly ( $p < 0.05$ ). Likewise, the HDL level was seen to be decreased in diseased animals and increased in treatment ( $p < 0.05$ , Table-3).

TBARS, the reflection of oxidative stress was observed to be increased in both plasma and heart homogenate of diseased animals and return back to normal level in treatment ( $p < 0.05$ , Table IV and V). The antioxidants like GSH, GPX and catalase were noticed to be decreased in plasma and heart homogenate of diseased animals ( $p < 0.05$ , Table- 4 and 4). Pretreating the animals with extract was noted to increase the level of antioxidants.

## DISCUSSION

EA is a rich source of phytoconstituents like tannin, Vitamin C and Vitamin E. Different extracts of EA point out the presence of different phytoconstituents (Table I). Among the different extracts of EA, 85 % methanolic extract contains most of the phytoconstituents like flavonoids, tannin, etc. Based on the presence of higher concentration of phytoconstituents, 85% methanolic extract of EA alone is taken for further pharmacological evaluation.

Hyperlipidaemia is observed in patients with NIDDM, obesity, hypertension, etc. Treatment with natural herbs is likely to be fraught with lesser side effects compared to the presently used synthetic oral hypolipidaemic agents. In this present research work, we have attempted to evaluate the hypolipidaemic and antioxidant activity of EA in fructose-induced hyperlipidaemia. Though the exact mechanism for the hypoglycaemic effect of EA has been reported earlier<sup>29</sup>, the hypoglycaemic effect might be related with insulin resistance. The hypocholesterolaemic effect of EA has not been reported earlier. This made us to select an animal model in which hyperglycaemia and hyperlipidaemia are involved.

Research findings on the molecular mechanism for the fructose-induced hyperlipidaemia are underway. Some mechanisms of high fructose diet induced hypertriglyceridaemia are insulin resistance in rats.<sup>29</sup> Although fructose in the diet alters the activity of several enzymes and regulates hepatic carbohydrate metabolism, leading to hepatic insulin resistance<sup>30</sup> and hypertriglyceridaemia<sup>31</sup> the

mechanisms by which an excess of fructose produces these effects are unknown.

Feeding rats with high dosage of fructose (>60% of total calories in diet) affects lipid metabolism and causes hyperlipidaemia<sup>32</sup> (Park et. al., 1992), insulin resistance, hyperinsulinaemia and mild hypertension, which are features associated with obesity-related hypertension. Fructose feeding evokes significant alterations particularly in liver TGL metabolism and is reported to be atherogenic due to induction of lipogenic enzymes in liver.<sup>33</sup> The use of 10 % fructose in drinking water for a period of 1 week or longer is equivalent to a diet containing 48-57 % by calories and has been found to be the most suitable one for the production of insulin resistance in rats.<sup>34</sup> In our study, administration of fructose for 21 days has significantly increased the glucose, insulin and triglyceride levels similar to an earlier study.<sup>35</sup> Administering EA (150 mg/kg) has prevented the development of hyperlipidaemia.

Lipid changes observed in fructose-treated rats are noted to have elevated levels of cholesterol, TGL, LDL, VLDL and HDL-C. Accumulation of cholesterol, TGL, VLDL and LDL is observed in tissues. These findings are consistent with the results of Michaelis et. al., 1975<sup>36</sup>. The increased conversion of Carbon from fructose in to glycerol-3-phosphate might be responsible for the elevated level of TGL in fructose-administered animals.<sup>37</sup> Feeding a high fructose diet to diabetic rats produces an increase in activity of HMG-CoA reductase and addition of fructose to cultured rat hepatocytes increases HMG-CoA reductase by approximately 3-fold.<sup>38</sup> The EA extract might be an inhibitor of HMG CoA reductase, which is responsible for the observed decrease in the level of lipid profile.

ROS can be formed in the heart, and other tissues, by several mechanisms; they can be produced by xanthine oxidase (XO), NAD (P) H oxidases, cytochrome P450, by auto-oxidation of catecholamine and by uncoupling of NO synthase (NOS).<sup>39</sup> Apart from lipid profile, we have also estimated the level of TBARS the marker of antioxidants in fructose administered animals. Since oxidative stress is the major factor responsible for the development of age related diseases and other cardiovascular diseases, we have estimated the antioxidants. The antioxidant activity of EA has been reported earlier in *in-vitro* studies.<sup>40</sup>

The ascorbic acid concentration of EA is reported in the Table I. Vitamin C can inhibit the formation of ox-LDL in *in-vitro* condition. Even if ascorbic acid is water-soluble and is not incorporated in LDL particles, it has been proposed that this Vitamin may prevent LDL particle oxidation by

scavenging free radicals and other reactive species in aqueous milieu.<sup>41</sup>

The concentration of flavonoids and polyphenolic compound of EA are mentioned in Table I. Arai et. al., (2000)<sup>42</sup> has noted that the intake of flavonoids inversely correlates with the plasma total cholesterol and LDL cholesterol concentrations. Polyphenols reduce the susceptibility of LDL to oxidation in *In-vitro*.<sup>43</sup>

### CONCLUSION

EA extract is a rich source of phytoconstituents. Among the different extracts of EA, 85% methanolic extract is rich in phytoconstituents. The pharmacological evaluation of EA has proved that, 85% methanolic extract of EA exhibits hypolipidaemic activity by decreasing the level of total cholesterol, LDL, VLDL, TGL and increasing the level of HDL. Likewise, the same extract also displays the antioxidant activity by increasing the activity of enzymatic antioxidants like GPx and

Catalase, non-enzymatic antioxidants like GSH along with the decrement of TBARS. In pharmaceutical companies, 85 % methanolic extract of EA can be used as a potent hypolipidaemic and antioxidant activity. In future, the mechanism of action and isolation of active compound responsible for the hypocholesterolaemic effect of EA should be carried out.

### ACKNOWLEDGEMENT

The authors are grateful to Prof. R. Sethuraman, Vice-Chancellor, SASTRA and his able administrative colleagues for encouraging this work and Dr. Karunanidhi, Chairman of Swamy Vivekananda College of Pharmacy for allowing us to complete this work. We also thank the Drugs and Pharmaceutical Division particularly Dr. G.J. Samathanam of Department of Science and Technology and Orchid fine chemicals, Chennai for providing funding for doing the experiment.

**Table-1: Concentration of phytoconstituent in raw herb and 85 % methanolic extract of *Enicostemma axillare***

S.No.	Sample	Concentration (%)	Concentration (%)
1.	Phenol	3.63 ± 0.56	0.0073±0.0003
2	Tannin	3.94± 0.78	0.0207±0.0004
3	Carbohydrate	4.4 ±0.31	0.0002±0.00003
4	Vitamin C	1.97±1.23	0.0232±0.0003
5	Vitamin E	1.98 ±0.23	0.0139±0.0002

Note: Values are Mean ± SD.

**Table-2: Qualitative analysis of phytoconstituents in different extracts of *Enicostemma axillare***

Phyto constituents	Hexane	Chloroform	Ethylacetate	85% Methanol
Alkaloids	+	+	-	-
Flavonoids	-	-	+	+
Polyphenolics	-	-	+	+
Phytosterol	+	+	+	+
Saponins	-	-	-	-
Fixed oils and fats	-	-	-	-
Carbohydrates	-	-	-	+
Amino acids and proteins	-	-	-	+

Note : (-) refers absent, (+) refers present

**Table-3: Effect of EA extract in plasma lipid profile of fructose induced hyperlipidemic rats**

Sample	Experimental model	Cholesterol (mg/dl)	TGL (mg/dl)	HDL (mg/dl)	VLDL (mg/dl)	LDL (mg/dl)
Plasma	Group 1	65.3 ± 1.2 a	70.8 ± 1.3 a	21.8 ± 0.2 b	14.16 ± 0.1 a	29.3 ± 0.2 a
	Group 2	175.2 ± 10.5 c	175.3 ± 9.5 b	13.3 ± 0.1 a	35.06 ± 0.3 b	126.8 ± 0.1 d
	Group 3	125.3 ± 8.3 b	85.4 ± 6.5 a	18.3 ± 0.2 ab	17.08 ± 0.1 a	89.92 ± 0.3 c
	Group 4	80.2 ± 5.5 ab	70.2 ± 5.2 a	19.2 ± 0.3 b	14.04 ± 0.1 a	52.96 ± 0.2 b
Heart	Group 1	4.2 ± 0.2 a	8.8 ± 0.3 a	2.9 ± 0.2 b	1.76 ± 0.1 a	0.46 ± 0.03 a
	Group 2	12.1 ± 0.5 c	19.3 ± 1.5 b	2.1 ± 0.1 a	3.86 ± 0.3 b	6.14 ± 0.5 c
	Group 3	7.3 ± 0.3 b	12.4 ± 1.0 ab	1.9 ± 0.2 a	2.48 ± 0.2 ab	2.92 ± 0.3 b
	Group 4	6.2 ± 0.5 ab	17.3 ± 0.2 ab	2.8 ± 0.3 b	3.46 ± 0.2 ab	0.6 ± 0.02 a

Note: Values are Mean ± SE. (n=6). Significant difference has been observed using one way ANOVA (DMRT). Values not sharing common alphabets are differ significantly at p<0.05.

**Table-4: Effect of EA extract in plasma antioxidants of fructose induced hyperlipidemic rats**

S.No.	Experimental model	TBARS (nMol of Malondialdehyde/ mg of protein)	GSH (µg of GSH/mg of protein)	GST (nMol of CDNB-GSH conjugate formed/min/mg of protein)
1.	Group 1	0.02 ± 0.006 ab	2.2 ± 0.05 b	1.3 ± 0.01 c
2.	Group 2	0.05 ± 0.01 b	1.4 ± 0.01 a	0.58 ± 0.02 a
3.	Group 3	0.02 ± 0.01 ab	1.75 ± 0.02 ab	0.89 ± 0.02 b
4.	Group 4	0.01 ± 0.008 a	2.0 ± 0.01 b	1.12 ± 0.01 c

Note: Values are Mean ± SE. (n=6). Significant difference has been observed using one Way ANOVA (DMRT). Values not sharing common alphabets are differ significantly at p<0.05.

**Table-5: Effect of EA extract in heart antioxidants of fructose induced hyperlipidemic rats**

S.No.	Experimental model	TBARS (nMol of Malondialdehyde/ mg of protein)	Catalase (µMol of H <sub>2</sub> O <sub>2</sub> used/min/mg of protein)	GSH (µg of GSH/mg of protein)	GST (nMol of CDNB-GSH conjugate formed/min/mg of protein)
1.	Group 1	0.34 ± 0.15 ab	33.39 ± 3.35 c	2.3 ± 0.02 d	1.2 ± 0.01 c
2.	Group 2	1.16 ± 0.01 b	1.34 ± 0.01 a	1.5 ± 0.01 a	0.6 ± 0.03 a
3.	Group 3	0.49 ± 0.03 ab	12.56 ± 9.65 b	1.8 ± 0.02 b	0.9 ± 0.01 b
4.	Group 4	0.25 ± 0.061 a	42.90 ± 4.05 d	2.1 ± 0.03 c	1.1 ± 0.02 c

Note: Values are Mean ± SE. (n=6). Significant difference has been observed using one Way ANOVA (DMRT). Values not sharing common alphabets are differ significantly at p<0.05.

## REFERENCES

1. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinai N, Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr, 2000, 130: 2243–50.
2. Aviram M, Modified LDL and atherosclerosis. N Eng J Med, 1993, 98: 1–9.
3. Blakely SR, Hallfrisch J, Reiser S, Prather E, Long-term effects of moderate fructose feeding on glucose tolerance parameters in rats. J Nutr, 1981, 111: 307–14.
4. Carew TE, Schwence DC, Steinberg D, Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect

- in the watanable heritable hyper lipidemic rabbit. Proc Natl Acad Sci USA, 1987, 87: 7725-29.
5. Carmona A, Freedland RA, Comparison among the lipogenic potential of various substrates in rat hepatocytes: The differential effects of fructose-containing diets on hepatic lipogenesis. J Nutr, 1989, 119: 1304-10.
  6. Carr AC, Zhu BZ, Frei B, Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res, 2000, 87: 349-54.
  7. Di Carlo G, Mascolo N, Lzzo AA, Capasso F, Flavonoids old new aspects of class of natural therapeutic drugs. Life science, 1999, 65: 337-53.
  8. Diniz YS, Cicogna AC, Padovanib CR, Santatana LS, Faine L, Diets rich in saturated and polyunsaturated fatty acids metabolic shifting and cardiac health. Nutrition, 2004, 20: 230-34.
  9. Dubois M, Giles MK, Hamilton JK, Reber PA, Smith R, Colorimetric methods for the determination of sugar and related substances. Anal chem, 1954, 28: 350-56.
  10. Ellman GL, Tissue sulphhydryl groups. Arch Biochem Biophys, 1959, 82: 70-77.
  11. Farnsworl S, Bingal M, Role of herbal in Indian system of medicine. An review Indian J. pharm, 1977, 34: 231-35.
  12. Folch J, Lees M, Stanley GHS, A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957, 226: 497-509.
  13. Foster LB, Dunn RT, Standard reagents for determination of serum triglycerides by colorimetric Hantzch condensation method. Clin Chem, 1973, 19: 338-40.
  14. Friedewald WT, Levy RI, Fredirckson D, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972, 8: 499-502.
  15. Holzl B, Paulweber B, Sandhofer, F Patsch JR, (St Johans Spital, Salzburg; and University of Innsbruck, Innsbruck; Austria). Hypertriglyceridemia and insulin resistance (Case Report). J Intern Med, 1998, 243:79-82.
  16. Shrishailappa B, Suresh B, *In vitro* antioxidant activity of *Enicostemma axillare*. J Health Sci, 2008, 54(5): 524-28.
  17. Jayashree VS, Kamat SY, Distribution of tocopherol (Vitamin E) in marine algae from Goa, West coast of India. Indian J Mar Sci, 1985, 14: 228-29.
  18. Kavimani S, Manisenthilkumar KT, Antitumor activity of *Enicostemma axillare* on Dalton's ascetic lymphoma. J Ethnopharmacol, 2000, 71: 349-52
  19. Kerry NL, Abbey M, Red wine and fractionated phenolic compounds prepared from red wine inhibits low-density lipoprotein oxidation in vitro. Atherosclerosis, 1997, 135: 93-102.
  20. Keys A., Edition, Coronary heart disease in seven countries. Circulation, 41 suppl, 1970, 1: I-1-I-198.
  21. Michaelis DC, Nace CS, Szepesi B, Demonstration of a specific metabolic effect of dietary disaccharides in the rat. J Nutr, 1975, 105: 1186-91
  22. Murali B, Upadhyaya UM, Goyal RK, Effect of chronic treatment with *Enicostemma littorale* bloom in non insulin dependent diabetic (NIDDM) rats. J Ethnopharmacol, 2002, 81: 199-204.
  23. Noll G, Pathogenesis of Atherosclerosis a possible relations to infection. Atherosclerosis, 1998, 140: S3-S9.
  24. Oohishi N, Yagi N, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Ann Biochem, 1979, 95: 351-58.
  25. Okwu DE, Phytochemicals, vitamins and mineral contents of two Nigerian medicinal plants. Int J Mol Med Adv Sci, 2005, 4: 375-81.
  26. Pamplona R, Portero-Otín M, Requenab J, Gredillaa R, Barja G, Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls, Mech Ageing Develop, 2002, 123(11): 1437-46
  27. Park OJ, Cesar D, Faix D, Wu K, Shackletonn CHL, Hellerstein MK, Mechanism of fructose induced hypertriglyceridemia in rats. Biochem J, 1992, 282: 753-57.
  28. Rai BB, *Enicostemma axillare* Blume in Malaria. Ind Med Gaz ,1946, 81: 506-17.
  29. Richmond W, Preparation and properties of a cholesterol oxidase from nocardia sp. and its application to the enzymatic assay of total cholesterol in serum, Clin Chem, 1973, 19: 1350-56.
  30. Sarojini Y, Nittala SS, Vitamin C content of some macroalgae of Visakhapatnam, East coast of India. Indian J Mar Sci, 1999, 28: 408-12.

31. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK, Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. *Circ Res*, 2002, 91:406–13.
32. Sinha KA, Colorimetric assay of catalase. *J Biochem*, 1972, 47: 389-94.
33. Sleder J, Chen YDI, Cully MD, Reaven GM, Hyperinsulinemia in fructose-induced hypertriglyceridemia in the rat. *Metabolism*, 1981, 29: 303-05.
34. Slinkard K, Singleton VL, Total phenol analysis: automation and comparison with manual methods. *Am J Enol Vitic*, 1977, 28: 49-55.
35. Spence JT, Koudelka AP, Tseng-Crank JC, Role of protein synthesis in the carbohydrate-induced changes in the activities of acetyl CoA-carboxylase and hydroxymethylglutaryl CoA reductase in cultured rat hepatocytes. *Biochem. J*, 1985, 227: 939–47.
36. Trease GE, Evans WC, Pharmacognosy, 14th ed. London: ELBS, Baillire Tindal, 1996.
37. Vikrant V., Grover JK, Tandon SS, Rathi SS, Gupta N, Treatment with extracts of *Momordica charantia* and *Eugenia jambolana* prevents hyperglycemia and hyperinsulinemia in fructose fed rats. *J Ethnopharmacol*, 2001, 76: 139-43.
38. Warnick GR, Bederson J, Albers JJ, Dextran-sulfate-Mg<sup>2+</sup> precipitation procedure for quantitation of high density lipoprotein cholesterol. *Clin Chem*, 1992, 28: 1379-88.
39. Wendel A, Glutathione peroxidase Methods *Enzymol*, 1981, 77: 325–33.
40. Yugarani T, Tan BK, Das M, Effects of polyphenolic natural protection against cancer by plant properenoids: Induction of mammalian anticatrinogenic enzymes. *Mini Rev.Med Chem*, 2002, 2: 596-610.
41. Zak B, Dickenman RC, White EC, Burnett H, Cherney PJ, Rapid estimation of free and total cholesterol. *Am J Clin Pathol*, 1954, 24: 1307-15.
42. Zavaroni I, Sander S, Scott S, Reaven GM, Effect of fructose feeding on insulin secretion and insulin action in the rat. *Metabolism*, 1980, 10: 970–73.

---

**\*Corresponding Author:** Dr. U. Subasini,  
Professor and Head (Pharmacognosy)  
Swamy Vivekanandha College of Pharmacy  
Elayampalayam, Thiruchengode - 637 205  
Tamilnadu, India  
EmailID : [oviya\\_subashini@hotmail.com](mailto:oviya_subashini@hotmail.com), [vrajamanickam@hotmail.com](mailto:vrajamanickam@hotmail.com)  
Fax No. : +91- 4288- 234417  
Tel. No. : +91- 4288 – 234417